SNN — Smith & Nephew plc

Summary of Smith & Nephew (SNN) Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 Revenue: $1.7 billion, up 6.2% underlying growth (8.3% reported), aided by a 210 bps foreign exchange tailwind.
• Full Year Revenue: $6.2 billion, reflecting a 5.3% underlying growth, exceeding guidance of ~5%.
• Trading Profit: $1.2 billion, up $162 million, resulting in a trading margin of 19.7%, a 160 bps improvement.
• Free Cash Flow: Increased by 52.5% year-on-year to $840 million, enabling a $500 million share buyback.
• Adjusted EPS: Grew by 21% to $1.02, benefiting from share buybacks and lower restructuring costs.
• Net Debt: Slightly increased to $2.76 billion, with a leverage ratio of 1.7x adjusted EBITDA.

2. Strategic Updates and Business Highlights

• Business Unit Performance: All three segments (Orthopaedics, Sports Medicine & ENT, Advanced Wound Management) grew over 5% in 2025.
• Innovation Focus: Over 60% of growth came from products launched in the last five years, with notable products including CATALYSTEM, REGENETEN, and ALLEVYN COMPLETE CARE.
• CORI Robot: Achieved record placements globally, with a significant impact on knee growth in accounts where CORI is established.
• Acquisition of Integrity Orthopaedics: Expected to enhance the Sports Medicine portfolio, particularly in rotator cuff repair with the TENDON SEAM product.

3. Forward Guidance and Outlook

• 2026 Revenue Growth: Expected at around 6%, with trading profit growth of approximately 8%, both on an organic basis.
• Trading Profit Guidance: Anticipated to be around $1.3 billion, including the impact of the Integrity acquisition.
• Cash Flow Expectations: Projected free cash flow for 2026 is around $800 million, with a continued focus on working capital management.

4. Bad News, Challenges, or Points of Concern

• China VBP Headwinds: Although the impact from Joint Repair in China has annualized, there remain concerns about the AET and ENT segments facing VBP headwinds in 2026.
• Skin Substitutes Market: Facing price reductions and potential volume declines in certain channels, particularly in mobile and physician office settings, which could affect overall revenue.
• Competitive Pressures: Increased competition in the handheld robotics space, particularly from Mako, which may impact market share in ASCs.

5. Notable Q&A Insights

• Joint Repair Growth: Management expressed confidence in Joint Repair growth post-VBP, citing balanced performance across geographies.
• Skin Substitutes: The company maintains a cautious outlook, expecting flat volumes but noting that certain products like OASIS are performing well.
• LANDMARK Knee Launch: Anticipated to ramp up in the second half of 2026, with initial launches focusing on cementless options.
• CORI Competition: Management emphasized CORI's versatility and competitive advantages over new entrants in the handheld robotics market.
• Capital Allocation Strategy: Focus remains on organic growth and strategic M&A, with a disciplined approach to capital deployment to ensure balanced growth and profitability.

Overall, Smith & Nephew reported a strong finish to 2025, with solid growth across all business units and a focus on innovation and strategic acquisitions. However, challenges remain in specific markets, particularly in China and skin substitutes, which management is actively addressing. The outlook for 2026 remains positive, with expectations for continued growth and improved profitability.